Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

exeltis czech s.r.o., praha array - 11275 drospirenon; 578 ethinylestradiol - potahovaná tableta - 0,03mg/3mg - drospirenon a ethinylestradiol

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

exeltis czech s.r.o., praha array - 19633 mikronizovanÝ levonorgestrel; 19414 mikronizovanÝ ethinylestradiol - potahovaná tableta - 0,15mg/0,03mg - levonorgestrel a ethinylestradiol

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

bayer ag, leverkusen array - 564 estradiol-valerÁt; 564 estradiol-valerÁt; 9125 dienogest; 564 estradiol-valerÁt; 9125 dienogest; 564 estradiol-valerÁt - potahovaná tableta - 3mg+2mg/2mg+2mg/3mg+1mg - dienogest a estradiol

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 8280 gestoden; 578 ethinylestradiol - potahovaná tableta - 0,06mg/0,015mg - gestoden a ethinylestradiol

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

bayer ag, leverkusen array - 17443 klathrÁt ethinylestradiol-betadexu; 11275 drospirenon - potahovaná tableta - 0,02mg/3mg - drospirenon a ethinylestradiol

Európai Unió - cseh - EMA (European Medicines Agency)

amneal pharma europe ltd - levodopy, karbidopy - parkinsonova choroba - antiparkinsonické léky - symptomatická léčba dospělých pacientů s parkinsonovou chorobou.

Európai Unió - cseh - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsonova choroba - antiparkinsonické léky - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

lobsor pharmaceuticals ab, uppsala array - 1645 levodopa; 12698 monohydrÁt karbidopy; 11197 entakapon - intestinální gel - 20mg/ml+5mg/ml+20mg/ml - levodopa, inhibitor dekarboxylasy a inhibitor comt

Európai Unió - cseh - EMA (European Medicines Agency)

viatris limited - klopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidla - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st elevace akutního infarktu myokardu, v kombinaci s asa u medikamentózně léčených pacientů vhodných pro trombolytickou terapii. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pro další informace viz bod 5.

Csehország - cseh - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 9054 moxonidin - potahovaná tableta - 0,2mg - moxonidin